Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 212Pb-MP0712 |
| Synonyms | |
| Therapy Description |
212Pb-MP0712 is a radioconjugate comprising a designed ankyrin repeat protein (DARPin) that specifically binds DLL3 conjugated to the radionuclide 212Pb, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 346). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 212Pb-MP0712 | MP-0712|MP 0712|MP0712|[212Pb]Pb-MP0712 | DLL3 Inhibitor 2 | 212Pb-MP0712 is a radioconjugate comprising a designed ankyrin repeat protein (DARPin) that specifically binds DLL3 conjugated to the radionuclide 212Pb, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 346). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07278479 | Phase Ib/II | 212Pb-MP0712 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Recruiting | USA | 0 |